Development of Novel Anti-CDH1/E-Cadherin Monoclonal Antibodies for Flow Cytometry, Western Blotting, and Immunohistochemistry

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Cadherin (CDH)-mediated extracellular homophilic binding is crucial for maintaining tissue homeostasis. The epithelial cell-cell adhesion molecule cadherin 1 (CDH1/E-cadherin) forms the adherens junctions in epithelial cells, and the loss of CDH1 facilitates the migration and invasion of carcinoma cells. Although several anti-CDH1 monoclonal antibodies (mAbs) are available for western blotting and immunohistochemistry (IHC), a highly sensitive anti-CDH1 mAb suitable for flow cytometry has not been developed. We developed anti-CDH1 monoclonal antibodies through a flow cytometry-based high-throughput screening. Two anti-CDH1 mAb clones, Ca1Mab-3 (IgG1, κ) and Ca1Mab-5 (IgG1, κ), reacted with human CDH1-overexpressed Chinese hamster ovary-K1 (CHO/CDH1) cells in flow cytometry. Furthermore, Ca1Mab-3 and Ca1Mab-5 recognize endogenous CDH1-expressing human luminal-type breast cancer cells, such as MCF-7, but not triple-negative breast cancer cells, like MDA-MB-231. The dissociation constant values of Ca1Mab-3 and Ca1Mab-5 for CHO/CDH1 were determined as 4.8 × 10−10 M and 1.3 × 10−9 M, respectively. Ca1Mab-3 and Ca1Mab-5 can detect endogenous CDH1 in western blotting and IHC using a cell block. Furthermore, Ca1Mab-5 is available for IHC in formalin-fixed paraffin-embedded tumor tissues. These results indicate that Ca1Mab-3 and Ca1Mab-5, established by the CBIS method, are versatile for basic research and are expected to contribute to clinical applications, such as tumor diagnosis and therapy.

Article activity feed